Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 8/20 | 0.45 |
| ▸ | AVPR1A | P37288 | 4/20 | 0.45 |
| ▸ | RPA1 | P27694 | 1/20 | 0.37 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 5/20 | 0.33 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.33 |
| ▸ | SMO | Q99835 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5525761 | 0.88 | OXTR (0.42) | OXTRAVPR1ARPA1SCN9AADORA2A | |
| SCHEMBL5519940 | 0.88 | RPA1 (0.38) | OXTRAVPR1ARPA1MALT1KDM1A | |
| SCHEMBL5525538 | 0.88 | OXTR (0.36) | OXTRAVPR1ARPA1MALT1AVPR2 | |
| SCHEMBL5524918 | 0.86 | RPA1 (0.47) | OXTRAVPR1ARPA1SCN9A | |
| SCHEMBL5524300 | 0.85 | CYP11B1 (0.37) | OXTRAVPR1AMALT1AVPR2SMO | |
| SCHEMBL5521042 | 0.85 | OXTR (0.42) | OXTRAVPR1A | |
| SCHEMBL5522108 | 0.84 | OXTR (0.39) | OXTRAVPR1AMALT1AVPR2SMO | |
| SCHEMBL5531773 | 0.84 | OXTR (0.39) | OXTRAVPR1ARPA1MALT1AVPR2 | |
| SCHEMBL5527852 | 0.83 | OXTR (0.36) | OXTRAVPR1AMALT1AVPR2SMO | |
| SCHEMBL5522027 | 0.83 | OXTR (0.39) | OXTRAVPR1ARPA1MALT1AVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| EP-1698626-A1 | AMIDOPYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219210-A1 | Amidopyrazole Derivative | PTGER1, PTGS1, PTGER2 | OXTR 1114/4885AVPR1A 2308/4885RPA1 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.